Glucocorticoid induced osteoporosis

Acta Clinica Croatica

Volumn 50, Issue 4, 2011, Pages 563-566

  Pranić Kragić, Anka ^a   Radić, Mislav ^a   Martinović Kaliterna, Dušanka ^a   Radić, Josipa ^a  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

Author keywords

Glucocorticoids; Secondary osteoporosis; Therapy

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; GLUCOCORTICOID; PARATHYROID HORMONE[1-34]; VITAMIN D;

ARTICLE; CANCELLOUS BONE; CLINICAL TRIAL (TOPIC); CORTICOSTEROID INDUCED OSTEOPOROSIS; CORTICOSTEROID THERAPY; FRACTURE; GLUCOCORTICOID INDUCED OSTEOPOROSIS; HUMAN; IATROGENIC DISEASE; LOW DRUG DOSE; LUMBAR SPINE; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; POSTMENOPAUSE; TREATMENT OUTCOME;

GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS;

EID: 84865153531     PISSN: 03539466     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Cutolo M, Seriolo B, Pizzorni C, Secchi ME, Soldano S, Paolino S, et al. Use of glucocorticoids and risk of infections. Autoimmun Rev 2008;8:153-52.
2. Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporosis Int 2002;13:777-87.
3. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporosis Int 2007;18:1319- 28.
4. Raisz LG. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J Clin Invest 2005;115:3318-25.
5. Parfitt AM, Villanueva AR, Foldes J, Rao DS. Relations between histologic indices of bone formation: implications for the pathogenesis of spinal osteoporosis. J Bone Miner Res 1995;10:466-73.
6. Ebeling PR, Atley LM, Guthrie JR, Burger HG, Dennerstein L, Hopper JL, et al. Bone turnover markers and bone density across the menopausal transition. J Clin Endocrinol Metab 1996;81:3366-71.
7. Weinstein RS. Glucocorticoid-induced osteoporosis. Rev Endocr Metab Disord 2001;2:65-73.
8. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. J Clin Invest 1998;102:274-82.
9. Prummel MF, Wiersinga WM, Lips P, Sanders GT, Sauerwein HP. The course of biochemical param- eters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab 1991;72:382-6.
10. Dempster DW. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 1989;4:137-41.
11. Ton FN, Gunawardene SC, Lee H, Neer RM. Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 2005;20:464-70.
12. Rackoff PJ, Rosen CJ. Pathogenesis and treatment of glucocorticoid-induced osteoporosis. Drugs Aging 1998;12:477-84.
13. Ruegsegger P, Medici TC, Anliker M. Corticosteroid-induced bone loss: a longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol 1983;25:615- 20.
14. Leonard MB. Glucocorticoid-induced osteoporosis in children: impact of the underlying disease. Pediatrics 2007;119 Suppl 2:S166-74.
15. Mazziotti G, Angeli A, Bilezikian JP, Canalis E, Giustina A. Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab 2006;17:144-9.
16. Weinstein RS, Chen JR, Powers CC, Stewart SA, Landes RD, Bellido T, et al. Promotion of osteoclast survival and antagonism of bisphosphonate- induced osteoclast apoptosis by glucocorticoids. J Clin Invest 2002;109:1041-8.
17. Kim HJ, Zhao H, Kitaura H, Bhattacharyya S, Brewer JA, Muglia LJ, et al. Glucocorticoids suppress bone formation viathe osteoclast. J Clin Invest 2006;116:2152-60.
18. Hong JM, Kim TH, Ross FP, Teitelbaum SL, Kim SY, Kim HJ. Calpain 6, a target molecule of glucocorticoids, regulates osteoclastic bone resorption viacytoskeletal organization and microtubule acetylation. J Bone Miner Res 2010. E-pub ahead of print.
19. Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE. Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum 2008;58:1674-86.
20. Bauer DC, Garnero P, Hochberg MC, Santora A, Delmas P, Ewing SK, et al. Pretreatment levels of bone turnover and the antifracture efficacy of alen- dronate: the fracture intervention trial. J Bone Miner Res 2006;21:292-9.
21. Seeman E, Delmas PD. Bone quality: the material and structural basis of bone strength and fragility. N Engl J Med 2006;354:2250-61.
22. Hruska KA, Teitelbaum SL. Renal osteodystrophy. N Engl J Med 1995;333:166-74.
23. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003;48:3224-9.
24. Berris KK, Repp AL, Kleerekoper M. Glucocorticoid-induced osteoporosis. Curr Opin Endocrinol Diabetes Obes 2007;14:446-50.
25. O'Ryan FS, Khoury S, Liao W, Han MM, Hui RL, Baer D, et al. Intravenous bisphosphonate-related osteone- crosis of the jaw: bone scintigraphy as an early indicator. J Oral Maxillofac Surg 2009;67:1363-72.
26. Lenart BA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008;358:1304-6.
27. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005;90:1294-301.
28. Armamento-Villareal R, Napoli N, Diemer K, Watkins M, Civitelli R, Teitelbaum S, et al. Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int 2009;85:37-44.
29. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2010. E-pub ahead of print.
30. Saag KG, Shane E, Boonen S, Marin F, Donley DW, Taylor KA, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007;357:2028-39.
31. Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, SEE K, et al. Effects of teriparatide versusalendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum 2009;60:3346-55.
32. Eastell R, Chen P, Saag KG, Burshell AL, Wong M, Warner MR, et al. Bone formation markers in patients with glucocorticoid induced osteoporosis treated with teriparatide or alendronate. Bone 2010;46:929-34.
33. Devogelaer JP, Adler RA, Recknor C, See K, Warner MR, Wong M, et al. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J Rheumatol 2010;37:141-8.
34. Dore RK, Cohen SB, Lane NE, Palmer W, Shergy W, Zhou L, et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 2010;69:872-5.